OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel ...

Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as ...

Recursion Pharmaceuticals continues to have a pipeline of drugs that might provide further validation for the company's ...

A new preclinical study published in Frontiers in Immunology finds that cannabidiol (CBD) may help slow the growth of HPV-positive head and neck squamous cell carcinoma (HNSCC) by activating the ...

Fusarium graminearum causes Fusarium head blight in cereals and stalk rot in maize, mainly affecting crops in the US, Canada, China, and parts of Europe.

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance. Initial Phase 1 monotherapy data for both RAS- ...

Creative Biolabs recently updated its antibody chip platform, expanding product arrays for phosphorylation signaling and cytokine detection. SHIRLEY, NY, UNITED STATES, May 27, 2025 /EINPresswire.com/ ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American ...

PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutate ...

Its effect on cancer growth will take some explanation. An important cellular pathway is the mitogen-activated protein kinase (MAPK) pathway, which plays a critical role in integrating external ...

“With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven ...